Skip to content
2000
Volume 24, Issue 3
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

Recent reports show coagulopathy as a potential complication and poorer outcome of coronavirus disease 2019 (COVID-19), especially in those with comorbid conditions such as diabetes and hypertension as thrombosis could result in stroke and heart attacks. Indeed, cardiovascular complications in COVID-19 account for 40% of mortality. Although there is no standard treatment protocol or guidelines for COVID-19, it is a common practice to use anti-inflammatory corticosteroids and anti-coagulants, especially for severe COVID-19 patients. It has also been confirmed that deficiencies of vitamin D and/or vitamin K can exacerbate premorbid cardiovascular and diabetes conditions associated with COVID-19, at least partially due to a higher incidence of coagulopathy. Here, we discuss the roles of vitamins D and K in general and in COVID-19-related coagulopathy. Moreover, the suggestion for proper supplementations of these vitamins in countering COVID-19 is provided.

Loading

Article metrics loading...

/content/journals/cpb/10.2174/1389201023666220527110455
2023-03-01
2024-11-11
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/1389201023666220527110455
Loading

  • Article Type:
    Review Article
Keyword(s): COVID-19; menaquinone; phylloquinone; SARS-CoV-2; Thrombosis; vitamin D
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test